Gilead Sciences will buy Kite Pharma—and its autologous CAR T-cell technology—for $11.9 billion. The acquisition will help Gilead build its oncology portfolio and boost its revenues.
from Cancer via ola Kala on Inoreader http://ift.tt/2xcH19U
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου